ImmunityBio, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
ImmunityBio reported Q2 2026 net product revenue of $50.7 million (up 92% YoY, 15% sequentially), with first-half 2026 revenue of $94.8 million (up 121% vs. H1 2025). The company achieved its eighth consecutive quarter of sequential revenue growth since ANKTIVA's commercial launch, driven by continued U.S. urologist adoption. Key milestones: FDA accepted sBLA for ANKTIVA plus BCG with PDUFA target date January 6, 2027; Emirates Drug Establishment granted broadest marketing authorization for ANKTIVA; signed exclusive supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG; maintained $357.4 million in cash and marketable securities as of June 30, 2026.
Why this rating
Strong commercial momentum (92% YoY revenue growth, 8 consecutive quarters sequential growth) and cash position significant for ~$690M market-cap biotech. FDA sBLA acceptance and new geographies material. However, H1 2026 adjusted net loss of $167.3M (24% of market cap annualized) shows runway pressure despite revenue growth.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.